- Home
- CRGX vs AUTL Comparison
CRGX vs AUTL Comparison
Compare CRGX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- AUTL
- Stock Information
- Founded
- CRGX 2021
- AUTL 2014
- Country
- CRGX United States
- AUTL United Kingdom
- Employees
- CRGX N/A
- AUTL N/A
- Industry
- CRGX
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRGX
- AUTL Health Care
- Exchange
- CRGX Nasdaq
- AUTL Nasdaq
- Market Cap
- CRGX 628.6M
- AUTL 590.8M
- IPO Year
- CRGX 2023
- AUTL 2018
- Fundamental
- Price
- CRGX $3.70
- AUTL $2.17
- Analyst Decision
- CRGX Hold
- AUTL Strong Buy
- Analyst Count
- CRGX 7
- AUTL 3
- Target Price
- CRGX $4.67
- AUTL $10.20
- AVG Volume (30 Days)
- CRGX 1.9M
- AUTL 1.1M
- Earning Date
- CRGX 03-20-2025
- AUTL 03-13-2025
- Dividend Yield
- CRGX N/A
- AUTL N/A
- EPS Growth
- CRGX N/A
- AUTL N/A
- EPS
- CRGX N/A
- AUTL N/A
- Revenue
- CRGX N/A
- AUTL $10,091,000.00
- Revenue This Year
- CRGX N/A
- AUTL $851.83
- Revenue Next Year
- CRGX N/A
- AUTL $224.65
- P/E Ratio
- CRGX N/A
- AUTL N/A
- Revenue Growth
- CRGX N/A
- AUTL 82.71
- 52 Week Low
- CRGX $3.00
- AUTL $2.07
- 52 Week High
- CRGX $33.92
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- CRGX 20.88
- AUTL 41.81
- Support Level
- CRGX $3.00
- AUTL $2.11
- Resistance Level
- CRGX $3.88
- AUTL $2.26
- Average True Range (ATR)
- CRGX 0.92
- AUTL 0.12
- MACD
- CRGX -1.00
- AUTL 0.01
- Stochastic Oscillator
- CRGX 5.99
- AUTL 27.78
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.